Peptide · Vial
Verified recordBPC 157
$9010mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Current batchBPC 004-012
Published result99.2% reported purity
EternaGen / GHK 006-031Peptide · Research use only
GHK-CU
From CA$55CAD
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Currently unavailable
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
GHK-CU, clearly explained.
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Overview
GHK-Cu has been studied in human cells and in a small number of topical wound-care studies. Those findings are specific to the formulation and delivery method; they do not tell us what an injectable research material would do.
GHK-Cu is the copper complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine. Published work spans fibroblast models, skin-delivery experiments and a limited set of topical wound studies.- Format
- Vial
- Available strengths
- 50mg · 100mg
- Batch
- GHK 006-031
- Purity
- 99.5%
Research at a glanceMechanistic and limited topical human evidence; injectable evidence limited
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- GHK-Cu
- Molecular formula
- Confirm in batch record
- Molecular weight
- 403.93 g/mol
- Storage and handling
- Protect from direct light. Refer to the batch record for compound-specific handling conditions.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- GHK 006-031
- Purity
- 99.5%
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Extracellular-matrix biology
Human fibroblast cultures have shown concentration-dependent changes in collagen and matrix-related markers.
Evidence so far: In-vitro human-cell evidenceQuestion 02
Topical wound research
An older controlled study evaluated a GHK-Cu gel as part of standardized care for diabetic neuropathic ulcers.
Evidence so far: Narrow topical human evidenceQuestion 03
Route matters
Topical or ex-vivo skin findings do not establish the safety or effects of an injectable product.
Evidence so far: Critical interpretation boundaryProposed mechanism
How researchers are investigating the mechanism.
GHK binds copper(II), a metal involved in multiple enzymes. Laboratory studies have reported changes in collagen synthesis, glycosaminoglycans and extracellular-matrix remodelling, but the effect depends on concentration, formulation and experimental system.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Cultured human fibroblasts exposed to GHK-Cu
- What researchers saw
- The study reported stimulation of collagen synthesis at low concentrations without a change in cell number.
- Why that is not the whole story
- A cell-culture response cannot establish a cosmetic, wound-healing or systemic clinical outcome.
Study 02Multicentre, randomized, evaluator-blinded topical gel study in diabetic neuropathic ulcers
- What researchers saw
- Investigators reported greater closure measures for plantar ulcers when the gel was added to standardized care.
- Why that is not the whole story
- The finding is formulation-, route-, wound- and care-protocol-specific and does not support injectable use.
Evidence gaps
What remains unknown?
- The amount of evidence for systemic or injectable administration is very limited.
- Formulation, copper stoichiometry, stability and route can materially change what is being studied.
- Evidence for a topical clinical formulation cannot be transferred to a research vial.
Primary sources
Check the original sources.
- Primary mechanistic studyMaquart et al. GHK-Cu and collagen synthesis in fibroblast cultures. FEBS Lett. 1988. PMID 3169264.
- Primary topical clinical studyMulder et al. GHK-Cu gel in diabetic neuropathic ulcers. Wound Repair Regen. 1994. PMID 17147644.
- Regulatory safety reviewU.S. FDA. GHK-Cu injectable-route safety considerations.
Related products
Continue comparing.
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity
Peptide · Vial
Verified recordTesamorelin
$11010mg
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.
Current batchTESA 003-040
Published result99.4% reported purity